Is Cogent Biosciences, Inc. (COGT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.0% / 30% | 15.0% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 4.0% / 33% | 15.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 25.5% / 33% | 96.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 4.0% / 33% | 15.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 25.5% / 33% | 96.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -73.7% | |
| Return on Assets (ROA) | -32.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$264M |
| Free Cash Flow | -$266M |
| Total Debt | $239M |
| Debt-to-Equity | 37.5 |
| Current Ratio | 14.2 |
| Total Assets | $938M |
Price & Trading
| Last Close | $36.87 |
| 50-Day MA | $37.20 |
| 200-Day MA | $24.15 |
| Avg Volume | 2.0M |
| Beta | 0.5 |
|
52-Week Range
$3.72
| |
About Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cogent Biosciences, Inc. (COGT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cogent Biosciences, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cogent Biosciences, Inc.'s debt ratio?
Cogent Biosciences, Inc.'s debt ratio is 4.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 25.5%.
What are Cogent Biosciences, Inc.'s key financial metrics?
Cogent Biosciences, Inc. has a market capitalization of $5.9B. Return on equity stands at -73.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.